Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years

Natalizumab (NTZ) has been used for treatment of highly active relapsing–remitting multiple sclerosis (MS). When stopping NTZ the risk of severe rebound phenomenon has to be considered. We aimed to investigate the use of NTZ in clinical routine and focused on identification of potential risk factors...

Descripción completa

Detalles Bibliográficos
Autores principales: Auer, Michael, Zinganell, Anne, Hegen, Harald, Bsteh, Gabriel, Di Pauli, Franziska, Berek, Klaus, Fava, Elena, Wurth, Sebastian, Berger, Thomas, Deisenhammer, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639988/
https://www.ncbi.nlm.nih.gov/pubmed/34857795
http://dx.doi.org/10.1038/s41598-021-02665-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639988/
https://www.ncbi.nlm.nih.gov/pubmed/34857795
http://dx.doi.org/10.1038/s41598-021-02665-6

Ejemplares similares